PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc.
(Nasdaq: KOD), a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases, announced
today that management will present at the following upcoming
investor conferences:
- Jefferies Healthcare Conference, June 7,
2023, 1:30 PM ET (10:30 AM PT), New York,
New York
- Goldman Sachs 44th Annual Global
Healthcare Conference, June 14, 2023,
7:40 PM ET (4:40 PM PT), Dana
Point, California
A live webcast of both presentations will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases. We are
focused on bringing new science to the design and manufacture of
next generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our antibody biopolymer conjugate
platform, or ABC Platform™, uses molecular engineering
to merge the fields of antibody-based and chemistry-based therapies
and is at the core of Kodiak's discovery engine. Kodiak's lead
investigational medicine, tarcocimab tedromer, is a novel anti-VEGF
antibody biopolymer conjugate being developed for the treatment of
retinal vascular diseases including diabetic eye diseases, the
leading cause of blindness in working-age patients in the developed
world, and wet age-related macular degeneration, the leading cause
of blindness in elderly patients in the developed world. The
tarcocimab clinical program is designed to assess the product
candidate's durability, efficacy and safety in major retinal
vascular diseases in parallel, through the GLEAM and GLIMMER
studies in diabetic macular edema, the BEACON study in retinal vein
occlusion, the GLOW study in non-proliferative diabetic retinopathy
and the DAYLIGHT study in wet age-related macular degeneration.
Phase 3 data across the tarcocimab clinical program are expected in
3Q2023. Kodiak has leveraged its ABC Platform to build a pipeline
of product candidates in various stages of development. KSI-501 is
our dual inhibitor antibody biopolymer conjugate targeting both
VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) and is being
investigated in a Phase 1 clinical study initially in patients with
diabetic macular edema. We are expanding our early research
pipeline to include ABC Platform based triplet inhibitors for
multifactorial retinal diseases. Kodiak is based in Palo Alto, CA. For more information, please
visit www.kodiak.com.
Kodiak®, Kodiak Sciences®,
ABC™, ABC Platform™ and the Kodiak logo are
registered trademarks or trademarks of Kodiak Sciences Inc. in
various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-investor-conferences-301837703.html
SOURCE Kodiak Sciences Inc.